CAR-T Therapy for Refractory Autoimmune Diseases

Sponsor
LiangZou
Study ID
NCT07059169
Status
Recruiting
Apply to this trial

Conditions

  • Autoimmune Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JY231 (JY231 injection) — DRUG
    JY231 injection is administered intravenously and produces autologous CAR-T cells in the patient's body some time after infusion.

Study Details

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with refractory autoimmune diseases. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of CD19 CAR-T in the treatment of refractory autoimmune diseases.

Key Dates

First listed
Jul 10, 2025
Start date
Aug 4, 2025
Status verified
Apr 2026
Primary completion
Dec 31, 2026
Completion
Mar 31, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CD19 CAR-T for the treatment of refractory autoimmune diseases
    CD19 CAR-T for the Treatment of refractory autoimmune diseases subjects who meet the inclusion criteria will receive intravenous JY231 injection. JY231 injection infusion will produce CAR-T cells in the body.

Primary Outcome Measure

Incidence of adverse events(AE) after infusion [ Time Frame: Day 28、Month 2、Month 3、Month 6、Month 12、Month 18、Month 24 ]

Central Contacts

Related Studies